SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: EX-1.1
Date Filed: 2025-08-15
Accession Number: 0001213900-25-077458
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025077458/ea024071103ex1-1_synergy.htm

Chunk 16 of 19
Word Count: 863
Character Count: 5575

Document Content:

HAVE TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED UPON, ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, THE REGISTRATION STATEMENT, THE TIME OF SALE DISCLOSURE PACKAGE, ANY PROSPECTUS AND THE FINAL PROSPECTUS. 17. Counterparts. This Agreement may be executed and delivered (including by facsimile transmission or electronic mail) in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. [Signature page follows] If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us. Very truly yours, SYNERGY CHC CORP. Name: Title: Confirmed as of the date first above written

on behalf of itself and as Representative of the
several Underwriters named on Schedule 1 hereto:

BANCROFT CAPITAL, LLC

Name:

Title:

SCHEDULE I

Underwriter Number of Shares

Bancroft Capital, LLC [●]

SCHEDULE II

Final Term Sheet

Issuer: Synergy CHC Corp. (the “Company”)

Symbol: SNYR

Securities: [●] shares of common stock, $0.00001 par value, $[●] per share (the “Common Stock”), of the Company

[●] shares of Common Stock underlying the Representative Warrants

Public offering price: $[●] per share of Common Stock

Over-allotment option [●] shares of Common Stock

Underwriting discount: $[●] per share of Common Stock

Expected net proceeds: Approximately $[●] million (after deducting the underwriting discount and estimated offering expenses payable by the Company).

Trade date: _________, 2025

Settlement date: _________, 2025

Underwriter: Bancroft Capital, LLC

SCHEDULE III

Free Writing Prospectus

None.

SCHEDULE IV

Written Testing-the-Waters Communications

None.

SCHEDULE V

List of Lock-Up Parties

Jack Ross

Jaime Fickett

Alfred Baumeler

J. Paul SoRelle

Nitin Kaushal

Scott Woodburn

EXHIBIT A

Form of Representative’s Warrant

EXHIBIT B

Form of Lock-Up Agreement

Bancroft Capital, LLC

501 Office Center Drive, Suite 130

Fort Washington, PA 19034

Ladies and Gentlemen:

The undersigned understands
that you propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) as the representative (the
“Representative”) of the several underwriters named therein with Synergy CHC Corp., a Nevada corporation (the “Company”),
relating to a proposed offering of shares of common stock, par value $0.00001 per share of the Company (the “Common Stock”).
Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.

In consideration of the foregoing,
and in order to induce you to participate in the Offering, and for other good and valuable consideration the receipt of which is hereby
acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representative (which consent may be withheld
in its sole discretion), the undersigned will not, subject to the provisions contained herein, during the period (the “Lock-Up
Period”) beginning on the date hereof and ending on the date ninety (90) days after the date of the final prospectus relating
to the Offering (the “Final Prospectus”), (1) offer, pledge, announce the intention to sell, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable
for shares of Common Stock (including without limitation, shares of Common Stock which may be deemed to be beneficially owned by the undersigned
in accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and securities
which may be issued upon exercise of a stock option or warrant), (2) enter into any swap or other agreement that transfers, in whole or
in part, any of the economic consequences of ownership of the shares of, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of shares of Common Stock or such other securities, in cash or otherwise, (3) file or cause to be filed any
registration statement with the Commission relating to the Offering of any shares of Common Stock or any securities convertible into or
exercisable or exchangeable for shares of Common Stock, or make any demand for or exercise any right with respect to the registration
of any such securities;, (4) complete any offering of debt or equity securities of the Company, other than entering into a line of credit
with a traditional bank; or (5) publicly announce an intention to effect any transaction specific in clause (1) through (4), as set forth
above.

The foregoing paragraph shall
not be deemed to restrict or prohibit the undersigned from establishing a trading plan pursuant to Rule 10b5-1 under the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), for the sale or transfer of Common Stock, provided that such plan does
not provide for any sales, transfers or other dispositions of Common Stock during the Lock-Up Period, and provided, further, that no filing
by any party under the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection therewith
during the Lock-Up Period.